The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hematologic Malignancies Market Research Report 2025
Synopsis
Hematological malignancies are myeloid and lymphatic tumors caused by disruption of normal hematopoietic function. They are classified into several common subtypes, generally consisting of leukemia, multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL).
The global Hematologic Malignancies market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Hematologic Malignancies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hematologic Malignancies.
Report Scope
The Hematologic Malignancies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hematologic Malignancies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hematologic Malignancies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer, Inc.
F. Hoffmann-LA Roche ltd
Sanofi-Aventis
Bristol-Myers Squibb Company
AbbVie, Inc.
Novartis AG
GlaxoSmithKline PLC
Johnson & Johnson Services, Inc.
Takeda Pharmaceutical
Segment by Type
Leukemia
Lymphoma
Multiple Myeloma
Others
Segment by Application
Chemotherapy
Radiotherapy
Immunotherapy
Stem Cell Transplantation
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hematologic Malignancies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Hematological malignancies are myeloid and lymphatic tumors caused by disruption of normal hematopoietic function. They are classified into several common subtypes, generally consisting of leukemia, multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL).
The global Hematologic Malignancies market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Hematologic Malignancies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hematologic Malignancies.
Report Scope
The Hematologic Malignancies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hematologic Malignancies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hematologic Malignancies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer, Inc.
F. Hoffmann-LA Roche ltd
Sanofi-Aventis
Bristol-Myers Squibb Company
AbbVie, Inc.
Novartis AG
GlaxoSmithKline PLC
Johnson & Johnson Services, Inc.
Takeda Pharmaceutical
Segment by Type
Leukemia
Lymphoma
Multiple Myeloma
Others
Segment by Application
Chemotherapy
Radiotherapy
Immunotherapy
Stem Cell Transplantation
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hematologic Malignancies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hematologic Malignancies Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Leukemia
1.2.3 Lymphoma
1.2.4 Multiple Myeloma
1.2.5 Others
1.3 Market by Application
1.3.1 Global Hematologic Malignancies Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Chemotherapy
1.3.3 Radiotherapy
1.3.4 Immunotherapy
1.3.5 Stem Cell Transplantation
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hematologic Malignancies Market Perspective (2019-2030)
2.2 Hematologic Malignancies Growth Trends by Region
2.2.1 Global Hematologic Malignancies Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hematologic Malignancies Historic Market Size by Region (2019-2024)
2.2.3 Hematologic Malignancies Forecasted Market Size by Region (2025-2030)
2.3 Hematologic Malignancies Market Dynamics
2.3.1 Hematologic Malignancies Industry Trends
2.3.2 Hematologic Malignancies Market Drivers
2.3.3 Hematologic Malignancies Market Challenges
2.3.4 Hematologic Malignancies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hematologic Malignancies Players by Revenue
3.1.1 Global Top Hematologic Malignancies Players by Revenue (2019-2024)
3.1.2 Global Hematologic Malignancies Revenue Market Share by Players (2019-2024)
3.2 Global Hematologic Malignancies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hematologic Malignancies Revenue
3.4 Global Hematologic Malignancies Market Concentration Ratio
3.4.1 Global Hematologic Malignancies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hematologic Malignancies Revenue in 2023
3.5 Hematologic Malignancies Key Players Head office and Area Served
3.6 Key Players Hematologic Malignancies Product Solution and Service
3.7 Date of Enter into Hematologic Malignancies Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hematologic Malignancies Breakdown Data by Type
4.1 Global Hematologic Malignancies Historic Market Size by Type (2019-2024)
4.2 Global Hematologic Malignancies Forecasted Market Size by Type (2025-2030)
5 Hematologic Malignancies Breakdown Data by Application
5.1 Global Hematologic Malignancies Historic Market Size by Application (2019-2024)
5.2 Global Hematologic Malignancies Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Hematologic Malignancies Market Size (2019-2030)
6.2 North America Hematologic Malignancies Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hematologic Malignancies Market Size by Country (2019-2024)
6.4 North America Hematologic Malignancies Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hematologic Malignancies Market Size (2019-2030)
7.2 Europe Hematologic Malignancies Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hematologic Malignancies Market Size by Country (2019-2024)
7.4 Europe Hematologic Malignancies Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hematologic Malignancies Market Size (2019-2030)
8.2 Asia-Pacific Hematologic Malignancies Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hematologic Malignancies Market Size by Region (2019-2024)
8.4 Asia-Pacific Hematologic Malignancies Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hematologic Malignancies Market Size (2019-2030)
9.2 Latin America Hematologic Malignancies Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hematologic Malignancies Market Size by Country (2019-2024)
9.4 Latin America Hematologic Malignancies Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hematologic Malignancies Market Size (2019-2030)
10.2 Middle East & Africa Hematologic Malignancies Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hematologic Malignancies Market Size by Country (2019-2024)
10.4 Middle East & Africa Hematologic Malignancies Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer, Inc.
11.1.1 Pfizer, Inc. Company Detail
11.1.2 Pfizer, Inc. Business Overview
11.1.3 Pfizer, Inc. Hematologic Malignancies Introduction
11.1.4 Pfizer, Inc. Revenue in Hematologic Malignancies Business (2019-2024)
11.1.5 Pfizer, Inc. Recent Development
11.2 F. Hoffmann-LA Roche ltd
11.2.1 F. Hoffmann-LA Roche ltd Company Detail
11.2.2 F. Hoffmann-LA Roche ltd Business Overview
11.2.3 F. Hoffmann-LA Roche ltd Hematologic Malignancies Introduction
11.2.4 F. Hoffmann-LA Roche ltd Revenue in Hematologic Malignancies Business (2019-2024)
11.2.5 F. Hoffmann-LA Roche ltd Recent Development
11.3 Sanofi-Aventis
11.3.1 Sanofi-Aventis Company Detail
11.3.2 Sanofi-Aventis Business Overview
11.3.3 Sanofi-Aventis Hematologic Malignancies Introduction
11.3.4 Sanofi-Aventis Revenue in Hematologic Malignancies Business (2019-2024)
11.3.5 Sanofi-Aventis Recent Development
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Detail
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Hematologic Malignancies Introduction
11.4.4 Bristol-Myers Squibb Company Revenue in Hematologic Malignancies Business (2019-2024)
11.4.5 Bristol-Myers Squibb Company Recent Development
11.5 AbbVie, Inc.
11.5.1 AbbVie, Inc. Company Detail
11.5.2 AbbVie, Inc. Business Overview
11.5.3 AbbVie, Inc. Hematologic Malignancies Introduction
11.5.4 AbbVie, Inc. Revenue in Hematologic Malignancies Business (2019-2024)
11.5.5 AbbVie, Inc. Recent Development
11.6 Novartis AG
11.6.1 Novartis AG Company Detail
11.6.2 Novartis AG Business Overview
11.6.3 Novartis AG Hematologic Malignancies Introduction
11.6.4 Novartis AG Revenue in Hematologic Malignancies Business (2019-2024)
11.6.5 Novartis AG Recent Development
11.7 GlaxoSmithKline PLC
11.7.1 GlaxoSmithKline PLC Company Detail
11.7.2 GlaxoSmithKline PLC Business Overview
11.7.3 GlaxoSmithKline PLC Hematologic Malignancies Introduction
11.7.4 GlaxoSmithKline PLC Revenue in Hematologic Malignancies Business (2019-2024)
11.7.5 GlaxoSmithKline PLC Recent Development
11.8 Johnson & Johnson Services, Inc.
11.8.1 Johnson & Johnson Services, Inc. Company Detail
11.8.2 Johnson & Johnson Services, Inc. Business Overview
11.8.3 Johnson & Johnson Services, Inc. Hematologic Malignancies Introduction
11.8.4 Johnson & Johnson Services, Inc. Revenue in Hematologic Malignancies Business (2019-2024)
11.8.5 Johnson & Johnson Services, Inc. Recent Development
11.9 Takeda Pharmaceutical
11.9.1 Takeda Pharmaceutical Company Detail
11.9.2 Takeda Pharmaceutical Business Overview
11.9.3 Takeda Pharmaceutical Hematologic Malignancies Introduction
11.9.4 Takeda Pharmaceutical Revenue in Hematologic Malignancies Business (2019-2024)
11.9.5 Takeda Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
